Pharmaceutical giant AstraZeneca is set to inject £300 million into UK drug development after halting a £200 million expansion and vaccine plant last year. The investment follows praise from drugmakers including AstraZeneca for a US-UK agreement aimed at increasing medicine prices in Britain in line with the Trump administration's new US pricing policies. The deal was finalised earlier in April. Sir Keir Starmer described the commitment as "significant," emphasising its potential to "futureproof thousands of jobs in Macclesfield and Cambridge ." Pascal Soriot, AstraZeneca’s chief executive, extended his gratitude to the government "for their efforts to improve access for patients." This announcement follows a period of uncertainty regarding the firm’s UK investments. Last year, AstraZeneca paused a planned £200 million expansion of its research site in Cambridge and subsequently scrapped proposals for a £450 million vaccine plant in Merseyside.…